SCHEMBL264970

SCHEMBL264970

C[CH]CC(N)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.50
SLC6A3 Q01959 2/20 0.41
SLC6A2 P23975 1/20 0.41
SCN4A P35499 3/20 0.41
AOC3 Q16853 2/20 0.39
SLC6A4 P31645 2/20 0.39
IDO1 P14902 2/20 0.38
TDO2 P48775 2/20 0.38
TSHR P16473 2/20 0.37
MAPK1 P28482 2/20 0.37
HIF1A Q16665 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
KDM4E B2RXH2 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10343725 0.80 ADRB2 (0.47) ADRB2SLC6A3SLC6A2SCN4AAOC3
SCHEMBL30481074 0.79 ATM (0.46) ADRB2SLC6A3SLC6A2SCN4AAOC3
SCHEMBL21009888 0.79 ATM (0.46) ADRB2SLC6A3SLC6A2SCN4AAOC3
SCHEMBL7928876 0.79 DPP4 (0.41) SLC6A3SLC6A2AOC3SLC6A4IDO1
SCHEMBL268751 0.79 ESR1 (0.43) SLC6A3SLC6A2TSHRHIF1ATDP1
SCHEMBL266309 0.78 SCN4A (0.45) SCN4A
SCHEMBL265739 0.77 PNMT (0.44) SCN4AAOC3
SCHEMBL265653 0.76 CYP1A2 (0.59) AOC3SLC6A4TSHRMAPK1TDP1
SCHEMBL390989 0.76 SLC6A4 (0.57) ADRB2SLC6A3SLC6A2SCN4AAOC3
SCHEMBL1977034 0.76 SLC6A4 (0.57) ADRB2SLC6A3SLC6A2SCN4AAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431378-B2 Aminotransferase, gene encoding the same, and methods of using them KANEKA CORPORATION (JP) 2013-04-30 US disclosed
US-20120164724-A1 NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM KANEKA CORPORATION (JP) 2012-06-28 US disclosed
US-8133705-B2 Aminotransferase, gene encoding the same, and method of using them KANEKA CORPORATION (JP) 2012-03-13 US disclosed
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them KANEKA CORPORATION (JP) 2010-11-11 US disclosed
EP-1889907-B1 NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME KANEKA CORP (JP) 2009-09-02 EP disclosed
EP-1889907-A1 NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME Kaneka Corporation (JP) 2008-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100285544-A1 Novel aminotransferase, gene encoding the same, and method of using them BCAT1, AGXT, ALDH7A1 ADRB2 4675/4885SLC6A3 1734/4885SLC6A2 1814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.